Endocrine Abstracts

Background: In mammalian cells, poly(ADP-ribose) polymerase-1 (PARP1) is among the earliest proteins to reach the site of DNA damage and play key roles in different cellular responses ranging from DNA repair to cell death. PARP-inhibitors are recommended in mono or combination therapy for a subset of breast and ovarian cancers with BRCAness type of DNA repair deficiency. In addition, current clinical trials are examining whether PARP-inhibitors can potentiate the efficacy of c...